← Human Trials & Peer-Reviewed Studies
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436
Plain-language guide to PMID 26407603 (2016): double-blind randomized controlled trial study of ACTH (Corticotropin) and Vasopressin in 20 subjects.
Key Facts
- PMID
- 26407603
- Journal
- Psychopharmacology
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Katz DA et al. (5 authors)
- DOI
- 10.1007/s00213-015-4089-5
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at ACTH (Corticotropin) and Vasopressin.
Arginine vasopressin type 1B receptor (V1B) receptor antagonism is considered a potential therapeutic for diseases with hypothalamic-pituitary-adrenal (HPA) axis dysregulation.
Who Took Part
The abstract describes 20 subjects taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Random assignment meant chance, not the researchers, decided who got ACTH (Corticotropin) and who got the comparison, which limits bias.
As a double-blind ACTH (Corticotropin) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with ACTH (Corticotropin) could be set against what happens without it.
In the crossover set-up each of the subjects took both ACTH (Corticotropin) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Adrenocorticotropic Hormone, Antidiuretic Hormone Receptor Antagonists, Gastrointestinal Diseases, Hydrocortisone, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System and Receptors, Vasopressin.
Author keywords: ACTH, Cortisol, Glucocorticoid and HPA axis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of ACTH (Corticotropin) and Vasopressin in 20 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2016 (Psychopharmacology), a journal based in Germany.
More context: the ACTH (Corticotropin) compound page and the Vasopressin compound page, all human trials.
Our Notes on the Compounds
ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.